Omeros Corp
NASDAQ:OMER
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Omeros Corp
NASDAQ:OMER
|
US |
|
M
|
Mfe-Mediaforeurope NV
MIL:MFEA
|
IT |
|
S
|
Sparebank 1 SMN
OSE:MING
|
NO |
Intrinsic Value
The intrinsic value of Omeros Corp (OMER) under the Base Case is 11.66 USD per share.
Compared with the current market price of 16.86 USD, the stock appears
Overvalued by 31% .
The intrinsic value is calculated using valuation multiples.
Do our valuations actually work? See backtest results .
Cheap or expensive for this stock?
This block shows whether today’s valuation is cheap or expensive compared with the stock’s own history, and what happened after similar valuations in the past.
We compare the gap between the stock’s price and our estimated value over time.
- Undervalued can still be historically expensive. The stock may trade below our estimated value, but usually offer an even bigger discount.
- Overvalued can still be historically cheap. The stock may trade above our estimated value, but usually carry an even higher premium.
Market expectations can differ from our model, which may not fully capture everything affecting the price. That is why some stocks regularly trade above our estimated value and others below it.
The scale and chart show how today’s valuation compares with the past. The cards summarize past returns and waiting times until the stock stopped being cheap or expensive. This can happen because the price changed, our estimated value changed, or both.
Only completed periods are included. These are past results, not forecasts. The usual historical range does not necessarily mean fair value.
Fundamental Analysis
What Omeros Does
Omeros Corp is a biotechnology company that develops medicines for serious diseases, especially disorders tied to inflammation, the complement system, and the brain and nervous system. Its work is centered on creating drug candidates in-house, testing them in clinical studies, and moving the most promising ones toward regulatory approval. The company does not sell a broad range of consumer products; it is a drug developer.
- Headquarters
- United States of America US
- Employees
- 175
- IPO date
- Oct 8, 2009
Omeros has no economic moat
Omeros Corp lacks an economic moat, leaving it vulnerable to competitive pressures and market challenges.
Read the full moat analysis
Revenue & Expenses Breakdown
Omeros Corp
Earnings Waterfall
Omeros Corp
The intrinsic value for Omeros Corp (OMER) under the Base Case is 11.66 USD.
Compared with the current market price of 16.86 USD, the stock appears Overvalued by 31% .